Your browser doesn't support javascript.
loading
Anti-Inflammatory Activity of Bullfrog Oil Polymeric Nanocapsules: From the Design to Preclinical Trials.
Amaral-Machado, Lucas; Oliveira, Wógenes N; Torres-Rêgo, Manoela; Furtado, Allanny A; Alencar, Éverton N; Fernandes-Pedrosa, Matheus F; Rocha, Hugo A O; Egito, Eryvaldo Sócrates Tabosa.
Afiliação
  • Amaral-Machado L; Graduate Program in Health Sciences, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil.
  • Oliveira WN; Graduate Program in Health Sciences, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil.
  • Torres-Rêgo M; Chemistry Institute, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil.
  • Furtado AA; Graduate Program of Pharmaceutical Sciences, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil.
  • Alencar ÉN; Graduate Program in Health Sciences, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil.
  • Fernandes-Pedrosa MF; Graduate Program of Pharmaceutical Sciences, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil.
  • Rocha HAO; Graduate Program in Health Sciences, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil.
  • Egito EST; Graduate Program in Health Sciences, Federal University of Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil.
Int J Nanomedicine ; 16: 7353-7367, 2021.
Article em En | MEDLINE | ID: mdl-34754189
BACKGROUND: Although bullfrog oil (BFO) exerts anti-inflammatory effects, it has undesirable properties limiting its use. METHODOLOGY: BFO nanocapsules (BFONc) were produced through nanoprecipitation, and their physicochemical and morphological properties were characterized. To evaluate the biocompatibility of the formulation, a mitochondrial activity evaluation assay was conducted, and cell uptake was assessed. The in vitro anti-inflammatory activity was evaluated by measuring reactive oxygen species (ROS), nitric oxide (NO), type-6 interleukin (IL-6), and tumor necrosis factor (TNF) levels. The in vivo anti-inflammatory effect was assessed by quantifying myeloperoxidase (MPO) levels using the carrageenan-induced paw edema model. RESULTS: BFONc showed a particle size of 233 ± 22 nm, a polydispersity index of 0.17 ± 0.03, and a zeta potential of -34 ± 2.6mV. BFONc revealed remarkable biocompatibility and did not induce changes in cell morphology. Furthermore, BFONc decreased ROS levels by 81 ± 4%; however, NO level increased by 72 ± 18%. TNF and IL-6 levels were reduced by approximately 10% and 90%, respectively. Significant in vivo anti-inflammatory activity was observed compared to dexamethasone. MPO levels were reduced up to 2 MPOs/mg. CONCLUSION: Taken together, the results pointed out the remarkable biocompatibility and anti-inflammatory effects of BFONc.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Nanocápsulas Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Int J Nanomedicine Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Brasil País de publicação: Nova Zelândia
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Nanocápsulas Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Int J Nanomedicine Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Brasil País de publicação: Nova Zelândia